ArticleBMC microbiology2026
Drug repurposing: antimicrobial and antibiofilm effects of MLS0315771 against Gram-positive bacteria.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The escalating prevalence of multidrug-resistant (MDR) and biofilm-forming Staphylococcus aureus has created an urgent demand for alternative therapeutic strategies beyond conventional antibiotics. In this study, we report for the first time the notable antibacterial and antibiofilm activities of MLS0315771, a competitive phosphomannose isomerase (MPI) inhibitor, against a broad range of Gram-positive bacteria. MLS0315771 exhibited notable inhibitory and bactericidal effects against Staphylococcus aureus and Enterococcus faecium. The MIC₅₀/MIC₉₀ values were 25/25 µM for MSSA, 12.5/12.5 µM for MRSA, and 6.25/6.25 µM for linezolid-resistant E. faecium. This compound also significantly delayed bacterial proliferation at subinhibitory concentrations and reduced mature biofilms in vitro. Time-kill assays revealed that MLS0315771 displayed time-dependent bactericidal activity comparable or superior to vancomycin. Proteomic profiling of S. aureus exposed to MLS0315771 and functional assays confirmed that MLS0315771 disrupts bacterial membrane integrity and induces depolarization, thereby impairing essential membrane functions. Checkerboard analyses further indicated that unsaturated long-chain fatty acids antagonized its antibacterial activity, supporting a membrane-targeting antibacterial mechanism. Moreover, MLS0315771 displayed low hemolytic activity and moderate, cell line-dependent cytotoxicity toward mammalian cells, suggesting a limited but measurable therapeutic window. Collectively, these findings demonstrate that MLS0315771 acts as a novel membrane-targeting antibacterial agent with notable antibacterial activity against MDR and biofilm-forming Gram-positive pathogens, highlighting its potential as a candidate lead compound for future antimicrobial development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.